Lantern Pharma Statistics
Total Valuation
Lantern Pharma has a market cap or net worth of $30.79 million. The enterprise value is $3.89 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Lantern Pharma has 10.76 million shares outstanding. The number of shares has decreased by -0.84% in one year.
| Current Share Class | 10.76M |
| Shares Outstanding | 10.76M |
| Shares Change (YoY) | -0.84% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 12.44% |
| Float | 7.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.19 |
| P/TBV Ratio | 1.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.31, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.31 |
| Quick Ratio | 7.79 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -53.03% and return on invested capital (ROIC) is -36.51%.
| Return on Equity (ROE) | -53.03% |
| Return on Assets (ROA) | -33.94% |
| Return on Capital (ROIC) | -36.51% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$909,140 |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.05% in the last 52 weeks. The beta is 1.57, so Lantern Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.57 |
| 52-Week Price Change | -27.05% |
| 50-Day Moving Average | 3.57 |
| 200-Day Moving Average | 4.96 |
| Relative Strength Index (RSI) | 36.37 |
| Average Volume (20 Days) | 49,982 |
Short Selling Information
The latest short interest is 165,564, so 1.54% of the outstanding shares have been sold short.
| Short Interest | 165,564 |
| Short Previous Month | 176,913 |
| Short % of Shares Out | 1.54% |
| Short % of Float | 2.08% |
| Short Ratio (days to cover) | 4.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -21.20M |
| Pretax Income | -17.75M |
| Net Income | -19.09M |
| EBITDA | -21.18M |
| EBIT | -21.20M |
| Earnings Per Share (EPS) | -$1.77 |
Full Income StatementBalance Sheet
The company has $28.05 million in cash and $291,244 in debt, giving a net cash position of $27.76 million or $2.58 per share.
| Cash & Cash Equivalents | 28.05M |
| Total Debt | 291,244 |
| Net Cash | 27.76M |
| Net Cash Per Share | $2.58 |
| Equity (Book Value) | 26.60M |
| Book Value Per Share | 2.47 |
| Working Capital | 26.32M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.23 million and capital expenditures -$14,593, giving a free cash flow of -$17.24 million.
| Operating Cash Flow | -17.23M |
| Capital Expenditures | -14,593 |
| Free Cash Flow | -17.24M |
| FCF Per Share | -$1.60 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |